Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7021 to 7035 of 8908 results

  1. Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism (IPG109)

    Interventional procedures, IPG109 - Issued: January 2005 --> This guidance has been replaced by NICE interventional procedure guidance 472.

    Withdrawn guidance

  2. Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis (IPG110)

    We have moved interventional procedures guidance 110 to become HealthTech guidance 66. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (DG55)

    We have moved Diagnostics guidance 55 to become HealthTech guidance 687. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)

    We have moved Diagnostics guidance 57 to become HealthTech guidance 708. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (DG59)

    We have moved Diagnostics guidance 59 to become HealthTech guidance 724. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Transperineal biopsy for diagnosing prostate cancer (DG54)

    We have moved Diagnostics guidance 54 to become HealthTech guidance 680. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)

    We have moved Diagnostics guidance 56 to become HealthTech guidance 690. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    We have moved Diagnostics guidance 58 to become HealthTech guidance 719. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

    We have moved Diagnostics guidance 6 to become HealthTech guidance 292. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)

    We have moved Diagnostics guidance 60 to become HealthTech guidance 729. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (DG62)

    We have moved Diagnostics guidance 62 to become HealthTech guidance 735. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (DG61)

    We have moved Diagnostics guidance 61 to become HealthTech guidance 730. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    This guidance has been updated and replaced by NICE healthtech guidance 598.

    Withdrawn guidance